The UK variant of the coronavirus (SARS-CoV-2) has been found in 11 people in the Netherlands so far: 5 people in the Amsterdam region, 5 people in the Rotterdam region and 1 person in the Nijmegen

In 2019, the calculated concentrations of nitrogen dioxide (NO2) and particulate matter (PM10) were below the European limit values ​​in almost the whole of the Netherlands. Locally, the limit value for nitrogen dioxide is still being exceeded.

As of 7 December 2020, RIVM has become a knowledge partner of the international Platform for Accelerating the Circular Economy (PACE).

If the European Medicines Agency (EMA) approves BioNTech/Pfizer’s COVID-19 vaccine next week, the first people in the Netherlands will receive the COVID-19 vaccine on Friday 8 January 2021.

During the first wave, the novel coronavirus (SARS-CoV-2) had a major impact on healthcare in the Netherlands. Many patients faced delays in appointments and treatments.

If all goes well, the first people in the Netherlands will be vaccinated against COVID-19 in early January. The logistics operation aims to start vaccination in the week of 4 January 2021.

RIVM is hosting an international workshop on new and emerging risks from chemicals on 20 and 21 February 2019.

Research by RIVM shows that the participants in the so-called tROM project, their supervisors and other people involved may have been exposed to chromium-6.

Recently, the EU-sponsored Vaccines and InfecTious diseases in the Ageing popuLation (VITAL) project was launched.

On November 19th 2018, RIVM organised an international expert meeting on a rare type of lymphoma that is associated with breast implants.